The neoadjuvant approach has become one of the most useful strategies in breast cancer (BC) treatment, especially for human epidermal receptor‐2 (HER‐2) positive and triple‐negative breast cancer (TNBC) types. The gene discussed is ERBB2; the disease is breast carcinoma.